INH6 is a potent Nek2/Hec1 inhibitor; inhibits the growth of HeLa cells with an IC₅₀ of 2.4 μM. IC50 & Target: IC50: 2.4 μM (HeLa), 1.7 μM (MB231), 2.1 μM (MB468), 2.5 μM (K562)^[1] In Vitro: Hec1 is an oncogene overly expressed in many human cancers. Small molecule INH (Inhibitor of Nek2/Hec1) targeting the Hec1 and its regulator, Nek2, in the mitotic pathway is identified to inactivate Hec1/Nek2 function mediated by protein degradation that subsequently leads to chromosome mis-segregation and cell death. INH6 treated cells exhibit increased mitotic population with multipolar spindle configurations. An increased rate of chromosome misalignment is detected upon treatment with INH6 of HeLa cells expressing the chromosome marker protein H2B-GFP. INH6 treated cells shows progressive morphological changes characteristic of dying cells (e.g., membrane bubbling), which is further confirmed by cell cycle profiling with FACS analysis. Approximately 20% of INH6 treated cells are apoptotic 72 hrs after treatment^[1].